Clinical trials: Acute Ischaemic Stroke
Acute Ischemic Stroke
The Vesalio NeVa Stent Retriever Study for Treatment of Large Vessel Occlusion Strokes
A prospective, open label, single-arm 90-day study designed to assess the safety, performance and efficacy of thrombus removal in subjects presenting with acute ischemic stroke with the NeVa stent retrievers.
- Trial name
- NCT03927001
- Testing
- NeVa Stent Retrievers
- Where
- Spain
- Volunteers
- 150 people
- Sponsor
- Vesalio
Acute Ischemic Stroke
Clinical Study of Desmoteplase in Japanese Patients With Acute Ischemic Stroke
The purpose of the study is to evaluate whether desmoteplase is safe and tolerated when given to Japanese patients with acute ischemic stroke
- Trial name
- DIAS-J (NCT01104467)
- Testing
- Desmoteplase
- Where
- 19 sites in Japan
- Volunteers
- 48 people
- Sponsor
- Lundbeck Japan K. K.
Stroke, Acute
Efficacy and Safety of Nerinetide in Participants With Acute Ischemic Stroke Undergoing Endovascular Thrombectomy Excluding Thrombolysis
The primary purpose of this study is to determine if a single dose of nerinetide can reduce global disability in people who have had a stroke and are selected for endovascular therapy without the use of a tissue plasminogen…
- Trial name
- ESCAPE-NEXT (NCT04462536)
- Testing
- Nerinetide
- Where
- 81 sites in United States, Australia and 7 more
- Volunteers
- 850 people
- Sponsor
- NoNO Inc.
Acute Ischemic Stroke
Acute Ischemic Stroke Interventional Study
To assess safety of single IV (bolus + infusion) doses of ACT017 in patients with an acute ischemic stroke in addition to best emergency standard of care (including fibrinolysis by rtPA with or without added thrombectomy), with a…
- Trial name
- ACTIMIS (NCT03803007)
- Testing
- Intravenous ACT017 1000 mg
- Where
- France
- Volunteers
- 160 people
- Sponsor
- Acticor Biotech
Stroke, Acute, Middle Cerebral Artery Stroke
Study of Human Placenta-derived Cells (PDA001) to Evaluate the Safety and Effectiveness for Patients With Ischemic Stroke
The primary objective of the study is to assess the safety and tolerability of Human Placenta-Derived Cells (PDA001) at 3 different dose levels versus placebo (vehicle control) administered intravenously in subjects following…
- Conditions
- Stroke, Acute, Middle Cerebral Artery Stroke, Posterior Cerebral Artery Stroke
- Trial name
- NCT01310114
- Testing
- Human Placenta-Derived Cells PDA001- (cenplacel-L)
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Celularity Incorporated
Acute Ischemic Stroke, Partial Anterior Circulation Infarct
DLBS1033 for Acute Ischemic Stroke Patients
This is a prospective, randomized, double-blind, and controlled clinical study to investigate the effects of DLBS1033 in conjunction with standard therapy compared to standard therapy alone in acute ischemic stroke patients.
- Conditions
- Acute Ischemic Stroke, Partial Anterior Circulation Infarct, Lacunar Anterior Circulation Infarct
- Trial name
- ADDLIST (NCT02133521)
- Testing
- DLBS1033
- Where
- 10 sites in Indonesia
- Volunteers
- 80 people
- Sponsor
- Dexa Medica Group
Ischemic Stroke
Cerebrolysin REGistry Study in Stroke
Investigation of clinical practices, safety and effectiveness of Cerebrolysin in routine treatment of patients with acute ischemic stroke.
- Trial name
- CREGS-S (NCT02541227)
- Testing
- Cerebrolysin
- Where
- Austria
- Volunteers
- 1,823 people
- Sponsor
- Ever Neuro Pharma GmbH
Acute Ischemic Stroke
A Study to Assess the Efficacy, Safety, and Pharmacokinetics of TB006 in Participants With Acute Ischemic Stroke
This multi-center, randomized, parallel-group, double-blind, placebo-controlled study will evaluate the efficacy and safety of TB006 in participants with an Acute Ischemic Stroke (AIS) event with 57 days of treatment.
- Trial name
- NCT05156827
- Testing
- TB006
- Sponsor
- TrueBinding, Inc.
Cerebral Infarction
Edaravone-Sodium Ozagrel Comparative Post-Marketing Study on Acute Ischemic Stroke
This study is randomized, Sodium Ozagrel (Thromboxane A2 Synthase Inhibitor) controlled study on acute ischemic stroke. The primary endpoints were the rate of patients with modified Rankin Scale score of 0-1 at 3 months.
- Trial name
- NCT00200356
- Testing
- Edaravone, Sodium Ozagrel
- Volunteers
- 401 people
- Sponsor
- Shionogi
Cerebrovascular Accident, Brain Ischemia
A Study of Effectiveness and Safety of Abciximab in Patients With Acute Ischemic Stroke (AbESTT-II)
The purpose of this study is to determine the effectiveness of abciximab in the treatment of acute ischemic stroke.
- Conditions
- Cerebrovascular Accident, Brain Ischemia, Acute Disease
- Trial name
- NCT00073372
- Testing
- Abciximab
- Volunteers
- 808 people
- Sponsor
- Centocor, Inc.
Acute Ischemic Stroke (AIS)
Study to Collect Real-world Performance and Safety Data on Penumbra System® in Population With Acute Ischemic Stroke (AIS).
The primary objective of this study is to collect real-world performance and safety data on the Penumbra System in a patient population with acute ischemic stroke (AIS)
- Trial name
- i-RISE (NCT07107022)
- Testing
- Penumbra System ®
- Where
- 12 sites in Australia, Canada and 3 more
- Volunteers
- 200 people
- Sponsor
- Penumbra Inc.
Stroke, Cerebral Ischemia
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
The primary purpose of this study is to determine whether a brief intravenous infusion of ancrod started within 6 hours of stroke onset improves functional outcome at 3 months.
- Conditions
- Stroke, Cerebral Ischemia, Brain Infarction
- Trial name
- NCT00141011
- Testing
- Ancrod (Viprinex)
- Where
- 100 sites in United States, Australia and 8 more
- Volunteers
- 277 people
- Sponsor
- Neurobiological Technologies
Ischemic Stroke
IMPACT- 24col Collateral Blood Flow Assessment Following SPG Stimulation in Acute Ischemic Stroke (ImpACT-24B Sub-Study)
The purpose of the ImpACT-24col sub-study is to explore effect of SPG stimulation on the augmentation of collateral blood flow and to relate it to the subject's cerebral blood flow status, the extent of the collateral vessel…
- Trial name
- NCT03396419
- Where
- Georgia
- Volunteers
- 1 people
- Sponsor
- BrainsGate
First-In-Human Study to Evaluate Safety of a New Drug Intended for Treatment of Acute Ischemic Stroke
A Phase 1 Study to Evaluate Safety and Tolerability of NoNO-42 in Healthy Adults
The purpose of this clinical trial is to evaluate the safety, tolerability and pharmacokinetics of a single ascending intravenous dose of NoNO-42 administered to healthy adults.
- Trial name
- NCT05636306
- Testing
- NoNO-42
- Where
- Canada
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- NoNO Inc.
Stroke
Safety and Efficacy of Alteplase When Administered in Chinese Patients With Acute Ischemic Hemispheric Stroke Where Thrombolysis is Initiated Between 3 and 4.5 Hours After Stroke Onset
To evaluate the safety and efficacy of alteplase when administered between 3 and 4.5 hours after onset of stroke symptoms in Chinese patients with acute ischemic stroke
- Trial name
- NCT02930837
- Testing
- alteplase
- Where
- 11 sites in China
- Volunteers
- 120 people
- Sponsor
- Boehringer Ingelheim
Acute Ischemic Stroke
Study of Compound Edaravone Injection for Treatment of Acute Ischemic Stroke
The primary objective of the study is to confirm the efficacy of compound Edaravone Injection via intravenous infusion every 12 hours in the patients with Acute Ischemic Stroke(AIS) in a double-blind, active-controlled manner.
- Trial name
- NCT04984577
- Testing
- Compound Edaravone Injection-Low dose, Compound Edaravone Injection-High dose, Edaravone Injection
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Nanjing Yoko Biomedical Co., Ltd.
Stroke
Desmoteplase in Acute Ischemic Stroke (DIAS)
The DIAS study (Part 2) was performed to support the dose finding of desmoteplase treatment in subjects with acute ischemic stroke selected by perfusion/diffusion mismatch on MRI within a time window of 3 to 9 h after…
- Trial name
- NCT00638781
- Testing
- Desmoteplase
- Where
- Germany
- Volunteers
- 104 people
- Sponsor
- PAION Deutschland GmbH
Acute Ischemic Stroke
Imaging Guided Patient Selection for Interventional Revascularization Therapy
The primary objective of this clinical evaluation is to determine the safety and effectiveness of the Penumbra System in a stroke cohort who presents within 8 hours from symptom and with a known core infarct volume at admission.
- Trial name
- START (NCT00963989)
- Testing
- Penumbra System
- Where
- United States
- Volunteers
- 146 people
- Sponsor
- Penumbra Inc.
Acute Ischemic Stroke
Study Evaluating Single Ascending Doses Of ILS-920
This is a first-in-human study of ILS-920. This study will provide an initial assessment of the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of ILS-920 after administration of ascending single…
- Trial name
- NCT00827190
- Testing
- ILS-920
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Acute Ischemic Stroke
rhPro-UK in Acute Ischaemic Stroke Within 4.5 Hours of Stroke Onset Trial 2(PROST-2)
Intravenous thrombolysis is the first-line therapy in patients with acute ischemic stroke within 4·5 hours of symptom onset, and recombinant tissue plasminogen activator (alteplase) is the preferred thrombolytic agent for this…
- Trial name
- PROST-2 (NCT05700591)
- Testing
- rhPro-UK, rt-PA
- Where
- 72 sites in China
- Volunteers
- 1,552 people
- Sponsor
- Tasly Biopharmaceuticals Co., Ltd.